Optimizing Stroke Prophylaxis of Acute Atrial Fibrillation With an Electronic Clinical Decision Support Tool
AF SWCRT-CDS
1 other identifier
interventional
36
1 country
1
Brief Summary
Atrial fibrillation (AF) is the most common arrhythmia in the world, with significant morbidity and mortality. With appropriate oral anticoagulation, the risk of stroke due to atrial fibrillation decreases by 64%. Although atrial fibrillation is commonly diagnosed and treated in the Emergency Department (ED), oral anticoagulation is significantly underprescribed. Underprescribing has been attributed to a lack of empowerment and deferral of prescribing to longitudinal care clinicians. Using a convergent parallel quantitative-qualitative design (mixed-methods), we propose a stepped-wedge cluster randomized trial design with the implementation of a clinical decision support (CDS) tool in adults with new-onset AF that are OAC-naïve and at significant risk for stroke. In parallel, we will use qualitative approaches to evaluate clinician facilitators and barriers to tool utilization as well as patient satisfaction and engagement with the tool.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable atrial-fibrillation
Started Jan 2022
Typical duration for not_applicable atrial-fibrillation
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 11, 2022
CompletedFirst Submitted
Initial submission to the registry
April 13, 2022
CompletedFirst Posted
Study publicly available on registry
April 22, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2026
CompletedMarch 20, 2025
March 1, 2025
4.1 years
April 13, 2022
March 17, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Number of patients appropriately prescribed OACs after CDS tool implementation.
The primary outcome is the number of patients appropriately prescribed OACs after CDS tool implementation.
through study completion, up to 4 years
Secondary Outcomes (1)
Clinician and patient feedback on acceptability and identification of barriers and facilitators to use of the tool.
through study completion, up to 4 years
Study Arms (3)
Link-Out
OTHERClinicians will be trained on the web-based portal of the CDS tool and shown where the Link to the tool will be available in the EHR.
BPA + Link-out
OTHERClinicians will be trained on how a BPA is triggered when a patient is diagnosed with AF. The alert will pop up within the EHR with the Link-out to the web portal.
BPA + FHIR
OTHERInstead of a link to the web-based portal, the BPA will contain a link to the FHIR-integrated CDS tool portal. FHIR will automatically pull EHR data about the patient into the CDS tool portal. Data include demographic information, comorbidities in the active problem list, past medical and surgical history, and social history. Clinicians will also receive training before the implementation of this step.
Interventions
Implementation of an EHR-based CDS tool for providers to use.
Eligibility Criteria
You may qualify if:
- A diagnosis of atrial fibrillation or paroxysmal atrial fibrillation (ICD-10 I48.0, I48.1, I48.9) during an ED visit with start dates between 1/11/2022 and 12/31/2025 within the patient's age \>18 years.
You may not qualify if:
- Valvular disease, pregnancy, large esophageal varices, thrombocytopenia, severe or uncontrolled bleeding, severe liver or kidney disease, major surgery within 72 hours; OR
- Recent brain, eye or spinal cord injury or surgery; OR
- ED stroke, death or hospitalization at index visit; OR
- Patient transferred from another hospital (to ensure availability of index ED visit data); OR
- Left against medical advice; OR
- Evidence of non-OAC naïve patient:
- OAC prescribed in the prior 3mo to index ED visit; OR
- Being managed by an anticoagulation clinic (ACC);
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Oregon Health & Science University (OHSU)
Portland, Oregon, 97239, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Bory Kea, MD, MCR
Oregon Health and Science University
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
April 13, 2022
First Posted
April 22, 2022
Study Start
January 11, 2022
Primary Completion
March 1, 2026
Study Completion
May 1, 2026
Last Updated
March 20, 2025
Record last verified: 2025-03
Data Sharing
- IPD Sharing
- Will not share